HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, March 29, 2019 (Pharmacist's Briefing) -- There are many unanswered questions about the safety and effectiveness of a drug used to combat hallucinations and delusions in Parkinson disease patients, says a report from a drug safety group. The nonprofit Institute for Safe Medication Practices (ISMP) called for Nuplazid to have stronger warnings on its label for patients and their families, CNN reported.
The U.S. Food and Drug Administration deemed the drug a "breakthrough" medication and gave it an expedited review, with approval granted in 2016. It is the only approved drug for Parkinson disease psychosis. But after the federal government received a high number of reports about deaths among patients taking Nuplazid, the FDA last year conducted a safety evaluation of the drug. The agency said it found no "new or unexpected" risks that were not already known at the time of the drug's approval and decided that no further action was needed, CNN reported.
However, the ISMP report released Wednesday says documents from the FDA evaluation of Nuplazid fail to answer a number of questions about the drug's safety and efficacy. As a result, the "reassurance" from the FDA was not warranted, according to the medical researchers, safety experts, and doctors who wrote the report.
The FDA refused to comment on the ISMP report. The agency said "in general the FDA does not comment on individual studies or reports, but evaluates them as part of the body of evidence to further our understanding about a particular issue and assist in our mission to protect the public health," CNN reported. The maker of Nuplazid, Acadia Pharmaceuticals, has stood by the drug. The company is under investigation by the Department of Justice for its sales and marketing of the medication.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.